Dyne is developing breakthrough medicines for serious muscle diseases based on its proprietary product platform, which delivers nucleic acids and other molecules to skeletal, cardiac and smooth muscle with unprecedented precision, potency and tolerability. Dyne went public in September 2020 (NASDAQ: DYN).
| Headquarters | Cambridge, MA |
| Website | www.dyne-tx.com |
| @Dyne_Tx | |
| Pipeline | Preclinical |